financetom
Business
financetom
/
Business
/
Regional lender 1st Source's Q3 net income rises on higher NII
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Regional lender 1st Source's Q3 net income rises on higher NII
Oct 23, 2025 1:41 PM

Overview

* 1st Source ( SRCE ) Q3 net income rises, driven by higher net interest income

* Diluted EPS for Q3 increases 21% yr/yr, reflecting strong financial performance

* Company raises quarterly dividend by 11% to $0.40 per share

Outlook

* Company did not provide specific guidance for future quarters or the full year in press release.

Result Drivers

* NET INTEREST INCOME - Higher rates on increased average loan and lease balances and lower short-term borrowing costs drove net interest income growth

* CREDIT LOSSES - Provision for credit losses decreased significantly, contributing to improved financial results

* INVESTMENT LOSSES - Realized losses from strategic repositioning trades in the investment portfolio negatively impacted noninterest income

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS $1.71

Q3 Net $42.27

Income mln

Q3 Net $88.75

Interest mln

Income

Q3 $1.47

Investme bln

nts

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the banks peer group is "buy."

* Wall Street's median 12-month price target for 1st Source Corp ( SRCE ) is $69.00, about 13.6% above its October 21 closing price of $59.65

* The stock recently traded at 10 times the next 12-month earnings vs. a P/E of 10 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Visa, Mastercard Unlikely to Yield Market Dominance Anytime Soon, UBS Says
Visa, Mastercard Unlikely to Yield Market Dominance Anytime Soon, UBS Says
Mar 11, 2025
12:31 PM EDT, 03/11/2025 (MT Newswires) -- Visa (V) and Mastercard ( MA ) continue to offer investors with a ready path to the broader payments and fintech sector, analysts at UBS said in a new research note on Tuesday. The credit card issuers provide a balanced exposure to traditional consumer spending as well as new payment methods, showing persistent...
Renault cuts 300 jobs at van factory as European market slows
Renault cuts 300 jobs at van factory as European market slows
Mar 11, 2025
PARIS (Reuters) - Renault Group will cut 300 jobs at a van factory in northern France, the carmaker said on Tuesday, responding to slowing European demand for commercial vehicles in the face of growing economic uncertainty. The French company, which is the European van market leader under its Renault brand, makes about 14% of its sales from the vehicles used...
Update: Endeavour Silver Jumps 18% as Q4 Adjusted Earnings Beat Analysts' Estimates
Update: Endeavour Silver Jumps 18% as Q4 Adjusted Earnings Beat Analysts' Estimates
Mar 11, 2025
12:17 PM EDT, 03/11/2025 (MT Newswires) -- (Updates shares.) Endeavour Silver ( EXK ) was last seen up 18% as the company beat analysts' adjusted earnings expectations for the fourth quarter. The company booked adjusted earnings, excluding most one-time items, of US$4.8 million, or US$0.02 per share, beating the analyst consensus loss per share forecast of US$0.01 compiled by FactSet,...
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Arvinas, Pfizer Breast Cancer Drug Fails To Show Progression-Free Survival Benefit In Trial
Mar 11, 2025
Arvinas, Inc. ( ARVN ) and Pfizer Inc ( PFE ). released topline results from the Phase 3 VERITAC-2 trial evaluating vepdegestrant monotherapy versus fulvestrant in adult patients with advanced or metastatic breast cancer. The results of the trial, released Monday, included estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer patients whose disease progressed following prior...
Copyright 2023-2026 - www.financetom.com All Rights Reserved